Another U.S. equity sector which is paying a rare visit to the ‘Oversold’ extremes region are the U.S. Biotechnology stocks. The Nasdaq Biotechnology Index has simultaneously registered a trifecta of a weekly oversold, a mean reversion to its 200 week moving average and a 2.5 standard deviation move below its rolling week mean. This current … Continue reading U.S. Biotechs are in a trough